Last updated: September 6, 2026
Cenegermin-bkbj, marketed as Oxervate by Dompé, is the first FDA-approved treatment specifically indicated for neurotrophic keratitis. Its commercial profile combines orphan-disease pricing, limited direct competition, complex biologic manufacturing and administration six times daily for eight weeks. The product has durable regulatory protection, but its revenue ceiling is constrained by a small diagnosed population, reimbursement friction and treatment-center logistics.
What is cenegermin-bkbj and how is it used?
Cenegermin-bkbj is a recombinant human nerve growth factor used to treat neurotrophic keratitis, a degenerative corneal disorder caused by impaired trigeminal innervation. Oxervate is supplied as a 0.002% ophthalmic solution and is administered as one drop six times daily at two-hour intervals for eight weeks.[1]
| Attribute |
Cenegermin-bkbj |
| Brand |
Oxervate |
| Sponsor |
Dompé farmaceutici S.p.A. |
| FDA product type |
Biologic license application |
| BLA |
761094 |
| FDA approval |
August 22, 2018 |
| Indication |
Neurotrophic keratitis |
| Strength |
0.002%, equivalent to 20 mcg/mL |
| Standard course |
One drop six times daily for eight weeks |
| Administration |
Topical ophthalmic |
| Primary U.S. commercial channel |
Specialty pharmacy and limited-distribution access |
| Reference-product status |
FDA-licensed biologic |
| Direct FDA-approved pharmacologic competitors |
None identified as of the latest public FDA records |
The treatment is differentiated from conventional artificial tears, anti-inflammatory drops and corneal-protective devices because it is intended to restore corneal healing through nerve growth factor activity rather than provide lubrication or mechanical coverage.
What is the FDA regulatory status of Oxervate?
The FDA approved Oxervate under the orphan-drug framework for neurotrophic keratitis. The pivotal clinical program included studies in patients with stage 2 or stage 3 disease, the stages associated with epithelial defects or corneal ulceration.[1]
The FDA label reports that a greater proportion of cenegermin-treated patients achieved complete corneal healing than vehicle-treated patients after the treatment period. The product was approved for adults and pediatric patients aged 2 years and older.[1]
What regulatory advantages does cenegermin-bkbj have?
Cenegermin-bkbj benefits from several structural advantages:
- It addresses a disease with no other FDA-approved drug specifically indicated for neurotrophic keratitis.
- Its orphan-drug designation supports market exclusivity and reimbursement positioning.
- Its biologic status creates a more demanding pathway for follow-on development than a conventional small-molecule generic.
- Its clinical use is concentrated among corneal specialists, which supports targeted commercial deployment.
The same regulatory profile creates limits. The indication is narrow, the disease is underdiagnosed and treatment requires frequent administration over a fixed eight-week course.
When does cenegermin-bkbj lose exclusivity?
Cenegermin-bkbj has separate regulatory protections that should be analyzed independently.
| Protection |
Relevant date |
Commercial effect |
| FDA approval |
August 22, 2018 |
Starts biologic reference-product and orphan-drug timelines |
| Orphan-drug exclusivity |
Expected to run to August 22, 2025 |
Blocks approval of the same drug for the same indication, subject to statutory exceptions |
| Biologic reference-product exclusivity |
Expected to run to August 22, 2030 |
Delays submission of a biosimilar application under the BPCIA |
| Patent protection |
Depends on each issued patent and terminal disclaimer |
May extend beyond regulatory exclusivity |
The 12-year biologic reference-product exclusivity period is generally calculated from the date of first licensure, while orphan-drug exclusivity is generally seven years from approval.[2,3] Regulatory exclusivity does not eliminate patent risk. A biosimilar applicant may challenge relevant patents before the 12-year data-exclusivity period ends, although commercial approval and launch remain subject to the biologic statutory framework and enforceable patents.
Any pediatric-exclusivity extension must be confirmed through FDA records for the specific product. Publicly available regulatory materials should not be treated as proof of a six-month extension unless FDA has formally granted it.
What patents protect cenegermin-bkbj?
Cenegermin-bkbj is protected by a patent estate covering the molecule, formulation, therapeutic use and potentially manufacturing or delivery attributes. A complete freedom-to-operate analysis requires review of issued patents, pending applications, terminal disclaimers, maintenance status and claim scope in each jurisdiction.
Unlike small-molecule drugs, Oxervate does not rely on the conventional Orange Book patent-listing framework. As a biologic licensed under a BLA, relevant U.S. patent disputes are generally addressed through the Biologics Price Competition and Innovation Act patent-exchange process and related litigation, rather than a conventional Orange Book Paragraph IV certification.[3]
Does Oxervate have Orange Book patents?
Oxervate is not analyzed as a standard Orange Book small-molecule product. The FDA Orange Book primarily covers approved drug applications under the Federal Food, Drug, and Cosmetic Act. Cenegermin-bkbj is licensed as a biologic under the Public Health Service Act, making the Purple Book and BPCIA framework more relevant.[2,3]
This distinction affects generic-entry analysis:
- A conventional ANDA applicant would not be the expected pathway for a biologic such as cenegermin-bkbj.
- A follow-on developer would generally pursue a biosimilar or interchangeable biosimilar application.
- Patent litigation would not necessarily present as a conventional Paragraph IV dispute.
- The absence of an Orange Book listing does not mean the product lacks patent protection.
How strong is the cenegermin-bkbj patent estate?
The estate is commercially meaningful because the product has several layers of protection beyond the active ingredient. Its strongest practical barriers are likely to be:
- clinical and regulatory know-how for neurotrophic keratitis;
- formulation stability for a protein administered to the eye;
- manufacturing controls for recombinant nerve growth factor;
- clinical evidence supporting corneal healing;
- physician and payer familiarity;
- limited market scale for a potential biosimilar entrant.
The patent estate is less secure if protection depends primarily on broad method-of-use claims that can be designed around by altering dosing, patient selection or disease staging. Formulation and manufacturing claims can be more difficult to evaluate because their enforceability depends on claim construction and whether a biosimilar manufacturer’s processes are discoverable or independently practiced.
No public record establishes an approved cenegermin-bkbj biosimilar, an active U.S. Paragraph IV challenge or a definitive settlement that creates a known launch date. The absence of a public challenge is commercially favorable to Dompé but does not prove that no patent risk exists.
What is the market size for neurotrophic keratitis?
The addressable market is limited by the size of the diagnosed and treatment-eligible population. Neurotrophic keratitis is associated with herpes infections, diabetes, ocular surgery, chronic topical medication exposure, corneal transplantation, trauma and other causes of corneal nerve damage.[4]
Market expansion depends on three steps:
- Identifying patients with reduced corneal sensitivity.
- Confirming stage 2 or stage 3 disease.
- Obtaining payer approval for a high-cost specialty ophthalmic biologic.
The largest commercial opportunity is not broad primary-care prescribing. It is deeper penetration among corneal specialists, ophthalmic surgeons and academic referral centers. Earlier diagnosis can expand the treated population, but it may also shift patients toward less severe disease where physicians and payers are more cautious about using an expensive biologic.
What products compete with Oxervate?
Oxervate has no direct FDA-approved pharmacologic competitor for its labeled indication, but it competes with a wide group of treatment alternatives.
| Competitive category |
Examples |
Competitive effect |
| Lubricating therapy |
Preservative-free artificial tears, ointments |
Low cost; limited ability to reverse nerve-related disease |
| Biologic tear substitutes |
Autologous serum tears, platelet-rich plasma |
Used in specialist practice; variable access and standardization |
| Corneal protection |
Bandage contact lenses, amniotic membrane products, tarsorrhaphy |
Can promote healing without an eight-week biologic course |
| Anti-infective and anti-inflammatory therapy |
Antibiotics, corticosteroids, immunomodulators |
Treat complications or associated inflammation |
| Surgical intervention |
Tarsorrhaphy, nerve procedures, corneal transplantation |
Used in refractory or advanced disease |
| Investigational regenerative products |
Cell, gene and neurotrophic approaches |
Longer-term competitive threat, not established substitutes |
This competitive structure gives Oxervate strong product differentiation but weak pricing insulation. Physicians can often combine or sequence alternative treatments, and payers may require evidence that lower-cost options were attempted first.
What drives the financial trajectory of Oxervate?
Dompé is privately held and does not provide the same product-level revenue detail as a public pharmaceutical company. Public filings do not establish audited annual Oxervate revenue, operating margin or product-level cash flow. Financial models that assign precise annual sales to Oxervate should therefore be treated as estimates rather than company-reported figures.
The revenue trajectory is shaped by five variables.
1. Net price per treatment course
Oxervate is priced as a specialty biologic rather than a conventional ophthalmic drop. The product is typically dispensed for an eight-week course, and the gross cost can be substantial before rebates, copay assistance and payer discounts.
Net revenue depends on:
- insurer approval;
- specialty-pharmacy dispensing;
- patient abandonment;
- assistance-program use;
- rebates and contractual discounts;
- replacement product for wasted or mishandled vials.
2. Patient identification
Neurotrophic keratitis is frequently diagnosed by ophthalmologists rather than primary-care physicians. Revenue growth requires screening for corneal sensitivity and referral of patients with persistent epithelial defects.
Dompé has commercial incentives to expand awareness among corneal specialists, but disease education increases expenses before it produces prescriptions. The market is therefore sensitive to sales-force productivity and referral-network development.
3. Reimbursement friction
A high-cost, short-duration therapy can produce strong revenue per treated patient but substantial administrative drag. Prior authorization, step therapy and medical-necessity documentation may delay treatment. Delays are clinically important because untreated stage 2 or stage 3 disease can worsen.
The product’s specialty-pharmacy model helps control distribution and patient support, but it also adds operational complexity and can increase time to therapy.
4. Treatment durability
Some patients achieve complete healing after one course, while others may require retreatment or additional interventions. Durable healing supports clinical value and limits recurring revenue per patient. Retreatment, if clinically appropriate and reimbursed, expands revenue per patient but is not guaranteed.
5. International expansion
Cenegermin has been commercialized outside the United States, including in Europe under the Oxervate brand. International revenue depends on country-specific health-technology assessments, tender systems, reference pricing and reimbursement negotiations. European approval does not produce U.S.-style pricing or market access.
Which companies are challenging cenegermin-bkbj?
No publicly established competitor has displaced Oxervate in the approved neurotrophic-keratitis market. Competition is fragmented across:
- manufacturers of amniotic membrane products;
- developers of corneal neuroregenerative therapies;
- providers of autologous serum and platelet-rich plasma;
- ophthalmic surgery companies;
- developers of cell and gene therapies.
A credible direct challenger would need to show comparable or superior corneal-healing results, obtain an ophthalmic biologic or drug approval, and overcome the operational advantage of an existing specialist-prescribing network.
Biosimilar competition is a longer-term risk. The 12-year biologic reference-product exclusivity period materially delays FDA biosimilar approval timing, and the small commercial market may not justify development costs unless the entrant can access broader indications or secure manufacturing efficiencies.
What generic or biosimilar launch scenarios exist?
Scenario 1: No near-term follow-on entry
This is the base case while reference-product exclusivity, patents or both remain effective. Dompé retains pricing control, subject to payer negotiations and therapeutic substitution.
Scenario 2: Biosimilar development after regulatory exclusivity
A biosimilar developer could pursue FDA approval after the statutory reference-product period, subject to patent litigation and interchangeability requirements. Uptake would depend on payer substitution policies and whether ophthalmologists view the product as clinically interchangeable.
Scenario 3: Non-biosimilar therapeutic substitution
A regenerative therapy, amniotic product or surgical approach could reduce Oxervate use without being legally classified as a biosimilar. This is the more relevant competitive risk before a true follow-on biologic reaches the market.
Scenario 4: Label or indication expansion
Expansion into additional corneal nerve disorders could raise the revenue ceiling, but it would require clinical evidence and FDA review. Broader labeling could also increase payer scrutiny and invite new competitive programs.
What patent litigation and settlement agreements affect Oxervate?
No publicly confirmed U.S. patent litigation or settlement agreement establishes a generic or biosimilar launch date for cenegermin-bkbj. Because the product is a biologic, the relevant dispute framework is the BPCIA rather than a conventional Orange Book Paragraph IV pathway.
The main litigation risk categories are:
- validity challenges to formulation or method-of-use patents;
- non-infringement claims based on a different manufacturing process;
- disputes over biosimilar patent disclosures;
- claims involving pediatric, dosing or disease-stage use;
- trade-secret or process disputes involving recombinant protein production.
How does cenegermin-bkbj compare with other ophthalmic biologics?
| Factor |
Cenegermin-bkbj |
Anti-VEGF biologics |
Amniotic membrane products |
| Primary disease |
Neurotrophic keratitis |
Retinal vascular and macular diseases |
Corneal surface disease and wounds |
| Administration |
Six drops daily for eight weeks |
Intravitreal injection |
Placement on or over the cornea |
| FDA competition |
Limited direct competition |
Multiple products |
Product-specific and fragmented |
| Market size |
Niche |
Large |
Moderate and procedure-linked |
| Main barrier |
Diagnosis, adherence and reimbursement |
Injection capacity and cost |
Procedure logistics and clinical preference |
| Follow-on risk |
Delayed biosimilar risk |
Established biosimilar and off-label risk |
Substitution and product fragmentation |
Cenegermin has a smaller market than major ophthalmic biologics but stronger indication-specific differentiation. Its financial trajectory is therefore more dependent on patient penetration and reimbursement than on broad volume growth.
Key Takeaways
- Cenegermin-bkbj is the first FDA-approved drug specifically indicated for neurotrophic keratitis.
- Oxervate received FDA approval on August 22, 2018, under BLA 761094.
- Orphan-drug exclusivity is expected to expire in August 2025, while biologic reference-product exclusivity is generally expected to run through August 2030.
- Oxervate is not a conventional Orange Book generic product; biosimilar and BPCIA analysis is more relevant.
- No publicly established biosimilar, Paragraph IV challenge or settlement provides a confirmed U.S. launch date.
- The commercial opportunity is constrained by a small diagnosed population, specialist prescribing and high reimbursement friction.
- The principal near-term competitive threats are alternative regenerative, surgical and corneal-protection therapies rather than conventional generic drops.
- Dompé does not publicly disclose audited product-level Oxervate revenue, so precise financial trajectories remain estimate-based.
- The product’s strongest economic defenses are indication specificity, clinical differentiation, manufacturing complexity and specialist-channel control.
FAQs
Is cenegermin-bkbj a biosimilar or a generic eye drop?
No. Cenegermin-bkbj is an FDA-licensed biologic. A future follow-on product would generally pursue the biosimilar pathway rather than an ANDA generic pathway.
Can Oxervate be used for dry eye disease?
Oxervate is approved for neurotrophic keratitis, not ordinary dry eye disease. Use outside the approved indication would be off-label and clinically distinct.
How long is an Oxervate treatment course?
The FDA-approved course is one drop six times daily for eight weeks.[1]
Does Oxervate permanently restore corneal nerves?
The product promotes corneal healing through nerve growth factor activity, but the FDA label does not establish universal permanent nerve restoration. Outcomes depend on disease cause, severity and recurrence risk.
What is the main investment risk for cenegermin-bkbj?
The central risk is limited market expansion. Even with high revenue per treated patient, growth can be constrained by diagnosis rates, payer controls, adherence to six-times-daily dosing and competition from non-biosimilar corneal-healing therapies.
References
-
U.S. Food and Drug Administration. (2018). Oxervate (cenegermin-bkbj) ophthalmic solution prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. FDA.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119.
-
Sacchetti, M., & Lambiase, A. (2014). Diagnosis and management of neurotrophic keratitis. Clinical Ophthalmology, 8, 571-579. https://doi.org/10.2147/OPTH.S45921
